Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management
Author:
Affiliation:
1. Division of Hematology; Mayo Clinic; Rochester Minnesota
Funder
Amyloidosis Foundation
International Waldenstrom's Macroglobulinemia Foundation
National CancerInstitue
Mayo Clinic
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25292/fullpdf
Reference139 articles.
1. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia;Owen;Semin Oncol,2003
2. Waldenstrom's macroglobulinemia;Dimopoulos;Best Pract Res Clin Haematol,2005
3. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study;Bjorkholm;Semin Oncol,2003
4. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia;Kyle;Semin Oncol,2003
5. The cellular origin and malignant transformation of Waldenstrom macroglobulinemia;Paiva;Blood,2015
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Epidemiological data, etiology, pathogenesis, risk factors, clinical manifestations, modern methods of diagnosis and treatment, prediction of the course of non-Hodgkin lymphoma (literature review);Experimental and Clinical Physiology and Biochemistry;2024-09-04
2. Waldenström macroglobulinemia presenting as bilateral bloody pleural effusion: A case report;Medicine;2024-06-14
3. Residential proximity to dioxin-emitting facilities and risk of non-Hodgkin lymphoma in the NIH-AARP Diet and Health Study;Environment International;2024-06
4. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia;Blood Advances;2024-03-28
5. Rituximab plus cyclophosphamide and dexamethasone <i>versus</i> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial;Haematologica;2024-01-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3